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Abstract
Approximately 27–36 million patients in Europe have one of the ~ 5.000–8.000 known rare diseases. These patients often 
do not receive the care they need or they have a substantial delay from diagnosis to treatment. In March 2017, twenty-four 
European Reference Networks (ERNs) were launched with the aim to improve the care for these patients through cross 
border healthcare, in a way that the medical knowledge and expertise travels across the borders, rather than the patients. 
It is expected that through the ERNs, European patients with a rare disease get access to expert care more often and more 
quickly, and that research and guideline development will be accelerated resulting in improved diagnostics and therapies. 
The ERN on Genetic Tumour Risk Syndromes (ERN GENTURIS) aims to improve the identification, genetic diagnostics, 
prevention of cancer, and treatment of European patients with a genetic predisposition for cancer. The ERN GENTURIS 
focuses on syndromes such as hereditary breast cancer, hereditary colorectal cancer and polyposis, neurofibromatosis and 
more rare syndromes e.g. PTEN Hamartoma Tumour Syndrome, Li Fraumeni Syndrome and hereditary diffuse gastric cancer.
Keywords Hereditary cancer · Cross border health care · European Reference Network · Rare diseases · Syndrome · 
Genetic
The pan‑European approach to rare diseases
The current state of rare diseases in Europe
Health systems in the European Union (EU) aim to provide 
high-quality, cost-effective care. For rare and complex dis-
eases, this is a challenge due to the fragmented knowledge 
about these diseases [1, 2]. Hence, patients with a rare dis-
ease often do not receive the care they need or experience 
significant delay to the correct diagnosis and treatment. 
Across Europe there is substantial variation in health care for 
patients with a rare disease, especially considering progno-
sis, quality of life, healthcare costs, available guidelines and 
patient information. A rare disease is defined as a condition 
that affects fewer than 1 in 2,000 people. It is estimated that 
6–8% of all people someday in their lives will face a rare 
disease [1]. In the EU there are approximately 27–36 million 
people who experience daily suffering from one of the 5000 
to 8000 known rare diseases.
The ERNs are focused on providing a system of care, in 
which the medical knowledge and expertise travels across 
the borders, rather than the patients. In case it is unavoidable 
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the patient will travel to the nearest foreign expertise centre. 
In addition to care, the ERNs provide a platform for edu-
cation, training, patient empowerment, the development of 
guidelines and research activities.
The objective of European Reference Networks
European reference networks (ERNs) are virtual networks 
of medical experts from all over Europe. ERNs are focused 
on rare or complex diseases that require highly specialized 
treatments and a combined effort of expert knowledge and 
resources. The ERNs aim to improve the care of patients 
with a rare disease [3, 4]. The European Commission Expert 
Group on Rare Diseases, in collaboration with EURORDIS, 
a European alliance of rare disease patient organisations, has 
identified themes in which all rare diseases will be classified. 
In March 2017, 24 ERNs were appointed to these themes by 
the Board of Member States of the European Union, which 
oversees the ERNs [3, 5]. These 24 ERNs unite more than 
900 expert teams from more than 300 hospitals and 150 
patient representatives from 25 European member states in 
the area of one or more themes [4–6]. At national level, 
many expertise centres for rare disease have been recog-
nized by their government in the last few years. The pro-
cedures and criteria for the establishment of an ERN and 
the selection of members are regulated in EU legislation. 
To become a member of an ERN, a hospital or healthcare 
institute needs national endorsement and must meet a num-
ber of general requirements set by the European Commis-
sion (such as recognition by the national government) and 
a number of theme-specific criteria for each ERN (such as 
minimum number of patients and demonstrable facts related 
to expertise).
Information and access to European Reference 
Networks
In the years to follow a healthcare professional in the EU 
can use the expertise of the relevant ERN via one of the 
(national) expertise centres involved in the ERN of interest 
[7]. Patients can request advice from the network through 
their local medical specialist. In practice, this means that 
the healthcare professional refers the patient to the nearest 
expertise centre in their own country, and then this expertise 
centre will, if necessary, present the case to other experts in 
the ERN.
The patients will be asked informed consent by their 
referring healthcare professional for discussing their case 
via the Clinical Patient Management System: the secure 
web-based application functioning as the platform where 
healthcare professionals from the European Reference Net-
works (ERNs) discuss real patient cases. The informed con-
sent form enables patients to participate and profit from the 
ERN at 3 levels: (1) to have their medical data shared with 
healthcare professionals in the ERN so that they may work 
together to support the patient’s care; (2) to have their de-
identified data being included in one or more ERN database 
or registry; (3) to be contacted about the possibility to par-
ticipate in a specific research project.
The ERN for genetic tumour risk syndromes 
(ERN GENTURIS)
The state of affairs in the field of hereditary cancer 
in Europe
Hereditary tumour syndromes are often characterized by 
an increased risk for common tumours such as breast and 
colorectal cancer, by the occurrence of cancer at a younger 
age and by tumours at multiple locations. More than forty 
different forms of hereditary cancer syndromes are known 
[8]. Currently in Europe the majority of patients with a 
genetic tumour risk syndrome is not yet recognized as such 
[9–13]. However, if the hereditary predisposition is known 
in time, risk management options can be provided to prevent 
cancer from occurring or to detect cancer at an early stage. 
Often this is related to a better prognosis in both the patient 
and his/her family as also other family member could have 
inherited the genetic predisposition causing the syndrome. 
In addition, patients with hereditary cancer can benefit from 
a treatment adapted to the hereditary predisposition [14–18].
The role of ERN GENTURIS in the field of hereditary 
cancer
The European Reference Network on Genetic Tumour Risk 
Syndromes (ERN GENTURIS) is the ERN in the field of 
hereditary cancer. ERN GENTURIS aims at all patients 
in Europe with a known hereditary cancer predisposition 
by integrated, multidisciplinary activities in the fields of 
care, guidelines, education and research directed towards 
improved identification, genetic diagnostics, cancer preven-
tion and treatment [19].
ERN GENTURIS is coordinated by N. Hoogerbrugge, 
MD, PhD from the Radboud university medical center and 
currently brings together 23 centres in the field of hereditary 
cancer from 12 European member states, as well as seven 
patient representatives [19]. Within ERN GENTURIS, the 
rare or complex syndromes are divided into four themes: 
(1) Neurofibromatosis; (2) Hereditary colorectal cancer 
and Polyposis; (3) Hereditary breast and ovarian cancer; 
(4) Other rare, mainly malignant, hereditary tumour risk 
syndromes such as PTEN Hamartoma tumour Syndrome 
(PHTS), Li-Fraumeni syndrome, hereditary melanoma 
(FAMM), and hereditary stomach cancer.
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The governmental structure of ERN GENTURIS includes 
a National Coordinators Board consisting of national repre-
sentatives for each of the participating member states. The 
national coordinators act as contact with all HCPs, national 
patient and professional organizations and networks in their 
country. They will disseminate centrally established output 
and if necessary “translate” this into national products. For 
member states where no HCP is found that fulfil the GEN-
TURIS criteria, an affiliated partner will act as national rep-
resentative for ERN GENTURIS. In this way, all member 
states will be involved in ERN GENTURIS and will have 
access to guidelines and registries. The ERN will collaborate 
with other European stakeholders like current scientific col-
laborations, medical societies and patient representatives.
More information about ERN GENTURIS and the par-
ticipating expertise centres and partners and their specific 
expertise can be found on the website of ERN GENTURIS 
(http://www.gentu ris.eu).
Network activities
The network is organized via closed biannual network meet-
ings and monthly executive committee meetings and task 
force meetings. Task forces are formulated to organize and 
stimulate six key functions of the ERN: (1) Coordination and 
management, (2) Organization of care, (3) Guidelines, out-
comes and quality, (4) Education and training, (5) Research, 
data registration and grants, and (6) Patient empowerment, 
communication and dissemination.
Organization of care The ERN GENTURIS is an expert 
reference network for patients with or suspected of having a 
genetic tumour predisposition syndrome. Only a physician 
can consult the network and/or refer a patient with any ques-
tion related to the health care pathway of these syndromes. 
This includes topics as identification, diagnostics, treatment 
and risk management. A triage system is in place to man-
age these incoming requests by complexity, and facilitate 
a suitable action from an answer from an individual local 
or international ERN expert to an answer after multidis-
ciplinary team discussion among experts within the ERN 
GENTURIS.
Guidelines The ERN GENTURIS will use her exper-
tise to develop guidelines for care. The approach used to 
develop guidelines will be based on the NICE process, 
including the GRADE, AGREE, and Delphi methodol-
ogy. For each syndrome a committee will be selected, con-
sisting of a core group and an extended group. The core 
group will consist of three people who cover the defined 
disciplines of the core multidisciplinary team of the syn-
drome. The extended group will cover relevant disciplines 
of the extended multidisciplinary team, including a patient 
representative. Each guideline will relate to one of six 
modules of the clinical pathways: (1) General description 
of the syndrome, (2) Identification of patients, (3) Sur-
veillance and follow-up, (4) Treatment of symptoms, (5) 
Prophylactic treatment, and (6) Psychosocial counselling.
Registry The ERN GENTURIS registry covers a stand-
ardised minimal dataset on genotype and phenotype which 
will be captured following international classifications and 
ontology’s. Patients who were referred to the ERN GEN-
TURIS and who gave permission on their ERN informed 
consent form for data registration will be included in the 
registry. Rules of governance are being established that will 
include procedures for reviewing data requests, data access 
and data sharing of pseudonymised data.
Conclusion
In the near future medical specialists can call upon the ERNs 
with healthcare questions related to patients with rare or 
complex diseases. European collaboration is essential, both 
for the care that is currently needed as for the continuous and 
sustainable improvement of care. In this respect, the ERNs 
will provide an important stimulus to improve the life of 
many patients with rare diseases.
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